Health
AAD 2025: Almirall presents early-stage pipeline progress and real-world evidence on demonstrating AK treatment success and patient satisfaction with Tirbanibulin
ORLANDO, Fla., March 07, 2025--Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology presents five scientific posters at the 2025 American Academy of Dermatology (AAD) Annual Meeting - including new data on tirbanibulin, a topical treatment for actinic keratosis (AK) and progress of its early-stage asset LAD191, a high-affinity monoclonal antibody targeting interleukin-1 receptor accessory protein (IL-1RAP). These presentations provide valuable insights into pati
About this update from Almirall Sa
[{"type":"image","alt":"Almirall HQ in Barcelona (Photo: Business Wire)","displaySize":"","headline":null,"caption":"Almirall HQ in Barcelona (Photo: Business Wire)","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":469,"url":"https://media.zenfs.com/en/business-wire.com/538061d01db96a00ecfee455c2b97b33"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qKSyAviTzGCyHZmA7e7Zpg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTkzODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/538061d01db96a00ecfee455c2b97b33","width":480,"height":469}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":210,"url":"https://media.zenfs.com/en/business-wire.com/80faa3bd48c04b7d7394d0836faf31fc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tehyu3.yswMydycuwsW.ew--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/80faa3bd48c04b7d7394d0836faf31fc","width":480,"height":210}}},{"type":"list","items":[{"val":[{"type":"text","content":"New data analysis on Tirbanibulin shows consistent treatment response for actinic keratosis (AK): data from phase IV and real-world evidence studies show consistently high levels of response as well as patient satisfaction.","length":223,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Presentation of phase I data of the early-stage pipeline asset LAD191, a high affinity monoclonal antibody targeting IL-1RaP (interleukin-1 receptor accessory protein), which is expected to impact immune-modulated skin diseases by blocking multiple proinflammatory pathways.","length":274,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Almirall´s strong presence at the AAD conference, sharing new data on Almirall’s dermatology and pipeline portfolio demonstrate its dedication to the medical community and patients living with skin diseases.","length":207,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":704,"olType":false},{"type":"text","content":"ORLANDO, Fla., March 07, 2025--(BUSINESS WIRE)--Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology presents five scientific posters at the 2025 American Academy of Dermatology (AAD) Annual Meeting - including ne...